Great Novel Therapeutics Biotech and Medicals Corporation (GNTbm) focuses on innovative oral new drug development for the treatment of advanced and refractory cancers. GNTbm is devoted to cancer immunotherapy, ranging from epigenetic modulators, tumor microenvironment regulators (TMRs) of new drug combinations, epigenetic immunoactivators, and immunoregulatory multi-kinase inhibitors, which can be applied to treat varieties of cancers and to meet the clinical needs of advanced and refractory cancers worldwide.

The main R&D core technologies, including the new drug combination platform for tumor microenvironment regulation, the epigenetic immunoactivator platform, and the immunoregulatory multiple-kinase inhibitor platform, are applied to the development of new drugs with innovative mechanisms in cancer immunotherapy. These oral innovative immune-regulating new drugs can activate the patient's immune system, remodel the tumor microenvironment, stimulate CTL to recognize and attack the tumor, and induce lasting immune memory, which can effectively improve the therapeutic benefits for patients with advanced and refractory cancers .

On the other hand, GNTbm has developed the new generation epigenetic modulator--- Tucidinostat (Chidamide) for the treatment of HR+/Her-2- advanced breast cancer, peripheral T-cell lymphoma, hepatocellular carcinoma (HCC) and other new cancers.

GNTbm independently develops new chemical entity (NCE) new drugs with innovative mechanisms and new drug combinations for cancer immunotherapy with better safety and superior efficacy, aiming at providing the unmet clinical needs of patients with advanced and refractory cancers.